The concern of generic competition has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, triggering questions about the future of similar pharmaceutical holdings. While initial periods saw significant gains, the exclusivity end has allowed the way for discounted copies, possibly reducing revenue and creating a significant hazard … Read More